Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 28+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Published

on

<!– Name:DistributionId Value:8740511 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:9aeab6e8-3252-4415-8292-416d46cfd6ad –>

New York, USA, Feb. 01, 2023 (GLOBE NEWSWIRE) — Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 28+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

RRMS is the most common subtype (approximately 87%), which is characterized by unpredictable acute attacks followed by periods of remission. The growing number of patients would raise the market and demand for treatments that may cure the sickness, motivating various firms to spend on studies, research, and development in order to give better treatment alternatives.Significant innovations in the treatment of patients with multiple sclerosis (MS) have primarily addressed the frequency of flare-ups in relapsing-remitting MS (RRMS). With the evolution of technology, there has been good success in MS research, particularly in the creation of novel and diverse treatments and therapies in the clinical trial phases, and some of them are in the final trial phases and might be market-ready. 

DelveInsight’s Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed, and pipeline relapsing-remitting multiple sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the relapsing-remitting multiple sclerosis pipeline domain.

Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report

Advertisement
Stake.com
  • DelveInsight’s relapsing-remitting multiple sclerosis pipeline report depicts a robust space with 28+ active players working to develop 28+ pipeline therapies for Relapsing-Remitting Multiple Sclerosis treatment. 
  • Key relapsing-remitting multiple sclerosis companies such as Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, and others are evaluating new drugs for relapsing-remitting multiple sclerosis to improve the treatment landscape.
  • Promising relapsing-remitting multiple sclerosis pipeline therapies in various stages of development include Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.
  • In March 2022, Pipeline Therapeutics is set to commence the Phase Ib/IIa clinical trial of its lead programme, PIPE-307, to treat relapsing-remitting multiple sclerosis (RRMS) patients.  The move comes after the company obtained clearance for its investigational new drug application from the US Food and Drug Administration (FDA) to launch the trial. An oral, selective muscarinic M1 receptor antagonist, PIPE-307, is being developed for restoring myelin to treat MS.
  • In July 2021, InnoCare received $125 million upfront in return for sharing rights to orelabrutinib, an orally-active BTK drug that can cross the blood-brain barrier and penetrate the central nervous system. It is currently in a phase 2 trial for relapsing-remitting multiple sclerosis (RRMS). The deal was back-ended with up to $812.5 million in milestone payments if the drug reaches development, regulatory and commercial milestones, and royalties on any future sales.

Request a sample and discover the recent advances in relapsing-remitting multiple sclerosis treatment drugs @ Relapsing-Remitting Multiple Sclerosis Pipeline Report

The relapsing-remitting multiple sclerosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage relapsing-remitting multiple sclerosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the relapsing-remitting multiple sclerosis clinical trial landscape.

Relapsing-Remitting Multiple Sclerosis Overview

Multiple sclerosis is the most common neurological disorder in young adults, with symptoms typically appearing between the ages of 20 and 40. Multiple sclerosis attacks the central nervous system’s axons, which are protected by myelin, also known as white matter. Relapsing-remitting multiple sclerosis is the most common type, accounting for approximately 85% of all multiple sclerosis patients. It is distinguished by relapses (or exacerbations) of symptoms followed by periods of remission, during which multiple sclerosis symptoms improve or disappear.

There are several unusual and rare types of multiple sclerosis. Some people with relapsing-remitting MS experience various multiple sclerosis symptoms that appear to be linked to specific triggers. Exacerbations (also known as recurrences, relapses, or seizures) are acute flare-ups of multiple sclerosis symptoms or the appearance of new symptoms that last for at least 24 h.

Find out more about relapsing-remitting multiple sclerosis treatment drugs @ Drugs for Relapsing-Remitting Multiple Sclerosis Treatment 

Advertisement
Stake.com

A snapshot of the Relapsing-Remitting Multiple Sclerosis Pipeline Drugs mentioned in the report:

Drugs Company Phase  MoA RoA
IMU-838 Immunic Phase III Dihydroorotate dehydrogenase inhibitors Oral
Fenebrutinib Roche Phase III Agammaglobulinaemia tyrosine kinase inhibitors Oral
Divozilimab Biocad Phase III CD20 antigen inhibitors Intravenous
Vafidemstat Oryzon Genomics Phase II Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors Oral
Temelimab GeNeuro SA Phase II Toll-like receptor 4 antagonists Intravenous
Elezanumab AbbVie Phase II RGMA protein inhibitors Intravenous

Learn more about the emerging Relapsing-Remitting Multiple Sclerosis pipeline therapies @ Relapsing-Remitting Multiple Sclerosis Clinical Trials

Relapsing-Remitting Multiple Sclerosis Therapeutics Assessment

The relapsing-remitting multiple sclerosis pipeline report proffers an integral view of relapsing-remitting multiple sclerosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report 

Advertisement
Stake.com
  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Intravenous, Intradermal, Oral, Subcutaneous, Intramuscular
  • Therapeutics Assessment By Molecule Type: Small Molecule, Gene Therapy, Peptide, Immunotherapy, Cell Therapy
  • Therapeutics Assessment By Mechanism of Action: Dihydroorotate dehydrogenase inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Lysine specific demethylase 1 inhibitors, Monoamine oxidase B inhibitors, Toll-like receptor 4 antagonists, RGMA protein inhibitors, CD20 antigen inhibitors
  • Key Relapsing-Remitting Multiple Sclerosis Companies: TG Therapeutics, Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, and others
  • Key Relapsing-Remitting Multiple Sclerosis Pipeline Therapies: Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.

Dive deep into rich insights for new drugs for relapsing-remitting multiple sclerosis treatment; visit @ Relapsing-Remitting Multiple Sclerosis Medications

Table of Contents

1. Relapsing-Remitting Multiple Sclerosis Pipeline Report Introduction
2. Relapsing-Remitting Multiple Sclerosis Pipeline Report Executive Summary
3. Relapsing-Remitting Multiple Sclerosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Relapsing-Remitting Multiple Sclerosis Clinical Trial Therapeutics
6. Relapsing-Remitting Multiple Sclerosis Pipeline: Late Stage Products (Pre-registration)
7. Relapsing-Remitting Multiple Sclerosis Pipeline: Late Stage Products (Phase III)
8. Relapsing-Remitting Multiple Sclerosis Pipeline: Mid Stage Products (Phase II)
9. Relapsing-Remitting Multiple Sclerosis Pipeline: Early Stage Products (Phase I)
10. Relapsing-Remitting Multiple Sclerosis Pipeline Therapeutics Assessment
11. Inactive Products in the Relapsing-Remitting Multiple Sclerosis Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Relapsing-Remitting Multiple Sclerosis Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the relapsing-remitting multiple sclerosis pipeline therapeutics, reach out @ Relapsing-Remitting Multiple Sclerosis Treatment Drugs

Related Reports

Multiple Sclerosis Market

Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, among others.

Advertisement
Stake.com

Multiple Sclerosis Epidemiology Forecast

Multiple Sclerosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Multiple Sclerosis Pipeline

Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, among others.

Relapsing Multiple Sclerosis Pipeline

Advertisement
Stake.com

Relapsing Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing multiple sclerosis companies, including ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, among others.

Chronic Progressive Multiple Sclerosis Pipeline

Chronic Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic progressive multiple sclerosis companies, including Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, among others.

Primary Progressive Multiple Sclerosis Pipeline

Primary Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key primary progressive multiple sclerosis companies, including Atara Biotherapeutics, AB Science, Sanofi, MediciNova, among others.

Advertisement
Stake.com

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Services

Healthcare Business Consulting

Healthcare Competitive Intelligence Services

Advertisement
Stake.com

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 


Advertisement
Stake.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Complyport’s new AI tool – ViCA.Chat – set to revolutionise compliance support services

Published

on

complyport’s-new-ai-tool-–-vica.chat-–-set-to-revolutionise-compliance-support-services

LONDON, June 14, 2024 /PRNewswire/ — ViCA.Chat, the Virtual Compliance Assistant powered by AI technology, is set to transform regulatory compliance consulting. Developed by ComplyMAP Group’s AI engineers and Complyport’s compliance consulting teams, ViCA redefines compliance support services and propels governance, risk and compliance consulting into a new era of innovation. 

Offering real-time assistance across a vast array of UK and EU regulatory frameworks, ViCA delivers unparalleled efficiency, detail and precision in disentangling and dealing with complicated regulatory frameworks.
The key differentiator of ViCA is its specialised and purposely constructed unique databases that leverage Complyport’s 22 years of regulatory expertise, combined with tailored AI training tools, enabling ViCA to operate as an experienced compliance consultant. A dedicated human support team continuously improves and updates ViCA’s knowledge and responses through a feedback loop process and quality assurance sessions. This powerful symbiosis of AI and human expertise sets ViCA apart and ensures businesses have the latest regulatory information instantaneously and seamlessly.
As a result, ViCA’s specialised regulatory database goes beyond readily available online resources which feature into traditional AI tools. ViCA offers exclusive insights, proprietary regulatory interpretations, historical data, bespoke and purposely structured compliance documentation and templates. With advanced scraping capabilities, ViCA also extracts relevant data from selected websites and publicly available information, ensuring an up-to-date and comprehensive understanding of compliance requirements across industries.
From agile fintech startups to established law firms, financial institutions, regulatory bodies, insurance providers, as well as compliance consultants, ViCA seamlessly adapts to unique compliance needs. Its user-friendly interface ensures navigating and analysing regulatory data is swift and intuitive, streamlining the compliance workflow.
“ViCA is a game-changer in how regulatory compliance advice will be provided in the future”, commented Luis Parra, Managing Director of ViCA. “With ViCA, compliance insights become available to all. No longer are regulated firms and responsible people overly dependent on advisors and compliance consultants. Through ViCA, the financial system will not only meet but exceed regulatory standards. Moreover, the level of information made available to the public will benefit society as a whole, in its interactions with the financial services sector.”
Among ViCA’s revolutionary features is its cost-effective model, allowing businesses to significantly reduce reliance on traditional spending with external consultants and advisors.
Visit ViCA.Chat to experience the future of compliance support.
Contact:
Name: Luis ParraTitle: Managing DirectorCompany: Vica.ChatTelephone: +44 20 7399 4980 Email: [email protected]
About ViCA.Chat:
ViCA.Chat is a revolutionary Virtual Compliance Assistant powered by cutting-edge AI technology, designed to demystify the complexities of regulatory compliance. Utilising Complyport’s 22 years of regulatory expertise, ViCA offers real-time assistance and guidance across a wide range of regulatory frameworks, setting a new standard for efficiency and precision in compliance support. From fintech start-ups to established law firms, financial services institutions, regulators, regulatory firms, compliance consultants and insurance firms, ViCA caters to the diverse needs of professionals across all levels in the broader UK financial services sector.
Visit ViCA.Chat to learn more.
Logo – https://mma.prnewswire.com/media/2439008/ViCA_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/complyports-new-ai-tool—vicachat—set-to-revolutionise-compliance-support-services-302173182.html

Continue Reading

Artificial Intelligence

LoRa and LoRaWAN IoT Market worth $32.7 billion by 2029- Exclusive Report by MarketsandMarkets™

Published

on

lora-and-lorawan-iot-market-worth-$32.7-billion-by-2029-exclusive-report-by-marketsandmarkets™

CHICAGO, June 14, 2024 /PRNewswire/ — The LoRa and LoRaWAN IoT Market is expected to reach USD 32.7 billion by 2029 from USD 8.0 billion in 2024, at a Compound Annual Growth Rate (CAGR) of 32.4 % during 2024–2029, according to a new report by MarketsandMarkets™.

Browse in-depth TOC on “LoRa and LoRaWAN IoT Market”
320 – Tables 58 – Figures294 – Pages
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144298529
Scope of the Report
Report Metrics
Details
Market size available for years
2018-2029
Base year considered
2023
Forecast period
2024–2029
Forecast units
Value (USD Billion)
Segments Covered
Offering, Network Deployment, Application, End User, and Region
Region covered
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
List of Companies in LoRa and LoRaWAN IoT
The Bosch Group (Germany),  Cisco (US), Orange SA (France), Comcast Corporation (US), Semtech (US), NEC Corporation(Japan), Tata Communications (India), AWS (US), Advantech (Taiwan), SK Telecom (South Korea), Murata (Japan), Kerlink (France), Actility (France), Digi International (US), MultiTech (US), Ezurio (US), Sensoterra (Netherlands), Nwave Technologies (US), RAKwireless (China), TheThings.io (Spain), Datacake (Germany), Milesight (China), LORIOT (Switzerland), Exosite (US), Orbiwise (Switzerland), Netmore Group (Sweden), and Radio Bridge Inc (US).
The LoRaWAN ecosystem influences development of tools, software libraries, and cloud-based platforms that streamline the creation, deployment, and management of IoT solutions. Continuously evolving, this ecosystem boasts a burgeoning array of vendors providing LoRa-compliant devices, gateways, and network management solutions. This vibrant competition within the ecosystem propels innovation while driving down costs for end-users. Moreover, the development of interoperable solutions fosters seamless integration and deployment of LoRaWAN networks, simplifying the implementation process for businesses and organizations. As the ecosystem continues to expand and mature, it empowers developers, system integrators, and IoT enthusiasts to unleash their creativity, accelerate time-to-market, and unlock the full potential of LoRaWAN technology in diverse applications and industries.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=144298529
Based on network deployment, the public network segment to hold the largest market size during the forecast period.
The robust security features integrated into public LoRaWAN networks play a significant role in driving the growth and adoption of LoRaWAN technology in the market. End-to-end encryption ensures that data transmitted between devices and gateways is protected from unauthorized access or interception, safeguarding sensitive information such as sensor readings, location data, and command messages. Message integrity checks verify the integrity of data packets, detecting any tampering or alteration during transmission and ensuring data authenticity and reliability. Additionally, mutual authentication mechanisms establish trust between devices and gateways, verifying the identity of both parties before allowing communication to occur. These security measures provide organizations and end-users with confidence in the integrity and confidentiality of their data, mitigating concerns related to data privacy, cybersecurity threats, and regulatory compliance. As a result, implementing robust security features in public LoRaWAN networks enhances trust and credibility in the technology, driving increased adoption and market growth as organizations seek reliable and secure connectivity solutions for their IoT deployments.
By offering, the services segment is expected to hold a higher growth rate during the forecast period.
IoT service providers are pivotal in driving adoption by developing vertical-specific solutions finely tuned to the distinct needs of industries like agriculture, healthcare, logistics, and smart cities. In agriculture, for instance, IoT services offer solutions for precision farming, crop monitoring, and livestock management, enabling farmers to optimize irrigation, monitor soil health, and enhance yields. Similarly, IoT services facilitate remote patient monitoring, asset tracking, and inventory management in healthcare, improving patient care, reducing costs, and ensuring compliance with regulatory standards such as HIPAA. In logistics, IoT services provide real-time tracking of shipments, fleet management, and predictive maintenance, enhancing supply chain visibility, efficiency, and reliability. For smart cities, IoT services offer solutions for traffic management, waste management, energy optimization, and public safety, transforming urban infrastructure and enhancing the quality of life for residents. By addressing industry-specific challenges, compliance requirements, and use cases, vertical-specific IoT solutions deliver tangible business value, driving adoption and fueling the growth of the IoT services market across diverse sectors.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=144298529
Asia Pacific is expected to hold a higher growth rate during the forecast period.
In the Asia Pacific region, where agriculture serves as a cornerstone of many economies, adopting IoT technologies, particularly LoRa and LoRaWAN, is revolutionizing traditional farming practices. LoRaWAN’s long-range connectivity and low-power consumption make it well-suited for deployment in rural agricultural settings, where access to reliable connectivity may be limited. Through LoRa-based IoT solutions, farmers can implement precision agriculture techniques to address pressing challenges such as water scarcity, soil degradation, and unpredictable weather patterns. LoRa-enabled sensors facilitate real-time monitoring of soil moisture levels, temperature, and humidity, allowing farmers to optimize irrigation schedules and conserve water resources. Remote sensing technologies powered by LoRaWAN enable farmers to gather actionable insights on crop health, pest infestations, and nutrient deficiencies, facilitating timely interventions and improving overall crop management practices. Furthermore, LoRa-based crop analytics platforms provide farmers with data-driven decision support tools, helping them optimize planting strategies, improve yield forecasting, and mitigate the impact of climate change on agricultural productivity. By harnessing the power of LoRa and LoRaWAN IoT solutions, farmers in the Asia Pacific region can increase yields, conserve resources, and enhance resilience to environmental challenges, driving the adoption and growth of the LoRaWAN IoT market in the agricultural sector.
Top Key Companies in LoRa and LoRaWAN IoT Market:
The major vendors covered in the LoRa and LoRaWAN IoT Market are The Bosch Group (Germany),  Cisco (US), Orange SA (France), Comcast Corporation (US), Semtech (US), NEC Corporation(Japan), Tata Communications (India), AWS (US), Advantech (Taiwan), SK Telecom (South Korea), Murata (Japan), Kerlink (France), Actility (France), Digi International (US), MultiTech (US), Ezurio (US), Sensoterra (Netherlands), Nwave Technologies (US), RAKwireless (China), TheThings.io (Spain), Datacake (Germany), Milesight (China), LORIOT (Switzerland), Exosite (US), Orbiwise (Switzerland), Netmore Group (Sweden), and Radio Bridge Inc (US). These players have adopted various growth strategies, such as partnerships, agreements and collaborations, new product launches, enhancements, and acquisitions to expand their footprint in the LoRa and LoRaWAN IoT Market.
Browse Adjacent Markets: Digitalization and Internet of Things (IoT) Market Research Reports & Consulting
Related Reports:
Perimeter Security Market- Global Forecast to 2029
Smart Cities Market – Global Forecast to 2028
Fleet Management Market – Global Forecast to 2028
Smart Water Management Market – Global Forecast to 2028
Rail Asset Management Market – Global Forecast to 2026
Get access to the latest updates on LoRa and LoRaWAN IoT Companies and LoRa and LoRaWAN IoT Industry
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:Mr. Aashish MehraMarketsandMarkets™ INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lora-and-lorawan-iot-market-worth-32-7-billion-by-2029–exclusive-report-by-marketsandmarkets-302172905.html

Continue Reading

Artificial Intelligence

Scoring a Seat at UEFA EURO 2024™ with Top-Performing AI-Powered TOSHIBA TV Lineup

Published

on

scoring-a-seat-at-uefa-euro-2024™-with-top-performing-ai-powered-toshiba-tv-lineup

HONG KONG, June 14, 2024 /PRNewswire/ — Football fans are in for a treat as they gear up for UEFA EURO 2024™ with Toshiba TV’s top-performing Gaming TV Z670. As the OFFICIAL TV OF UEFA EURO 2024™, Toshiba TVs present immersive viewing of the football game by their AI-powered TV lineup. To celebrate the brilliant moments it can bring, Toshiba TV are gifting USD100 Amazon Gift Card via their social platform! By simply like, follow and comment on @ToshibaTVGlobal, fans can boost their chances of scoring this prize.

Optimized Visuals Tailored for Football Dynamics
The Toshiba REGZA Engine ZRi in Z670 transports football fans into the heart of the action. With the AI Football Mode, they’ll be able to see fast-moving objects crystal clear and football field actions much enriched. To see their favourite player score that winning goal, the AI Picture Optimizer automatically adjusts visual contrast and precision adapted to the game. From vivid green fields and vibrant player kits, every play comes to life with AI 4K Upscaling and Quantum Dot Color, transforming lower-resolution broadcasts into near-4K quality and unleashing lifelike visual color.
Powerful Audio Effects for a Live Stadium Experience
The Toshiba TV Z670’s powerful audio system makes viewers feel like they’re right in the game. With the REGZA Bass Woofer Pro, Tru Bass Booster, and Dolby Atmos, they’ll experience heart-thumping 3D surround sound that captures the live stadium atmosphere. Whether it’s the roar of the crowd or the intensity of each play, the rich audio brings the excitement of each game right into their room.
Bringing Everyone Together for UEFA EURO 2024™
Available in sizes ranging from 55″ to 85″, Z670 is equipped with a Wide Viewing Angle and Anti-reflection features that ensures a clear picture from all viewing positions with the non-glare panel. Gather everyone for “Brilliant Every Moment” in UEFA EURO 2024™ with Toshiba TV!
Please find the high-resolution TVC here: Link
About Toshiba TV:
With 70+ years of history in TV production, Toshiba TV is known for its exquisite craftsmanship, innovative ideas and groundbreaking inventions. By prioritizing superior image quality and auditory experiences, Toshiba TV sets new standards in entertainment. Toshiba TV stems from the excellence quest of customers, providing the world with responsible products to make the world a better place. Emphasizing attention to product details and technological advancement, Toshiba TV integrates aesthetically pleasing design, quality assurance, and brand reputation to underscore its commitment to authenticity in the actual world and a sincere dedication to its consumers, showcasing Toshiba TV’s long-standing design philosophy and continuous pursuit of product quality.
Photo – https://mma.prnewswire.com/media/2438761/image_5030810_27421259.jpgLogo – https://mma.prnewswire.com/media/2438760/image_5030810_27421181_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/scoring-a-seat-at-uefa-euro-2024-with-top-performing-ai-powered-toshiba-tv-lineup-302172970.html

Continue Reading

Trending